Emcure strengthens board by including 4 new independent directors

Emcure Pharmaceuticals on Tuesday said it has strengthened its board with the inclusion of four new independent directors, including former Foreign Secretary Vijay Keshav Gokhale.

emcure
.
Press Trust of India New Delhi
2 min read Last Updated : Jul 27 2021 | 9:07 PM IST

Emcure Pharmaceuticals on Tuesday said it has strengthened its board with the inclusion of four new independent directors, including former Foreign Secretary Vijay Keshav Gokhale.

The others who have joined the company's board are Shailesh Ayyangar, Hitesh Jain and Vidya Yeravdekar.

Earlier this year, Berjis Desai had taken over as the chairman of Emcure Board.

The company has had a long-standing tradition of appointing a Chairman from amongst its independent directors since 1997.

"We are delighted to have highly accomplished industry stalwarts as part of our board. New members' combined experience and wider perspective from their respective fields, will play an instrumental role in strengthening our strategic operations to grow in domestic and international markets," Emcure Pharmaceuticals Managing Director & CEO Satish Mehta said in a statement.

The drug firm aims to further augment its strengths as one of the fastest growing pharmaceutical companies in India with a global reach of over 70 countries across the world.

The addition to the leadership team reflects its commitment towards enriching its expertise and strengthening its operations for future growth, the drug firm noted.

The new members' collective strength across legal, pharma spectrum, policy developments and academics will provide additional thrust to the company's growth trajectory, it added.

Gokhale, a former IFS officer, has served as Indian Foreign Secretary while Ayyangar served as Managing Director in his latest stint at Sanofi and was the member of International Leadership Team and Country Chair for India & South Asia.

Jain is the Managing Partner at Parinam Law Associates while Yeravdekar is an eminent educationist.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :EmcureIndependent directorsboard of directors

First Published: Jul 27 2021 | 9:07 PM IST

Next Story